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HDL THERAPEUTICS ABSTRACT
It has long been recognized that elevated levels of low-density
lipoprotein cholesterol (LDL-C) increase the risk of cardiovascular
disease (CHD) and that pharmacologic therapy to decrease LDL-C
significantly reduces cardiovascular events. Despite the effectiveness
of statins for CHD risk reduction, even optimal LDL-lowering therapy
alone fails to avert 60% to 70% of CHD cases. A low plasma
concentration of high-density lipoprotein cholesterol (HDL-C) is also
associated with increased risk of CHD. However, the convincing
epidemiologic data linking HDL cholesterol (HDL-C) to CHD risk in an
inverse correlation has not yet translated into clinical trial evidence
supporting linearity between HDL-C increases and CHD risk reduction.
It is becoming clear that a functional HDL is a more desirable target
than simply increasing HDL-C levels. Discoveries in the past decade
have shed light on the complex metabolic and antiatherosclerotic
pathways of HDL. These insights, in turn, have fueled the development
of new HDL-targeted drugs, which can be classified according to four
different therapeutic approaches: directly augmenting the
concentration of apolipoprotein A-I (apo A-I), the major protein
constituent of HDL; indirectly augmenting the concentration of apo A-I
and HDL cholesterol; mimicking the functionality of apo A-I and
enhancing reverse cholesterol transport. This review discusses the
latest in novel HDL directed therapeutic strategies.

TOPIC: HDL C – Does it matter?
An update on novel HDL-C directed therapeutic strategies
INTRODUCTION:
An estimated 16.3 million persons, or 7.6% of the United States
population, have
coronary heart disease (CHD) (1). Cardiovascular disease is responsible
for 811,940
or 32.8% of all deaths in the United States on an annual basis (1).
Focused risk
reduction therapies are indicated for patients with CHD and those at
significant risk to
reduce events and improve survival rates.
The relationship between low density lipoprotein cholesterol (LDL-C)
and high density
lipoprotein cholesterol (HDL-C) and the development of CHD is widely
acknowledged.
In addition, the cardiovascular benefit for lowering LDL-C for those with
CHD is now
well established (2). Current treatment strategies for reducing CHD risk
are insufficient
to prevent most CHD events and suggest therapies for increasing
HDL-C in addition to
reducing LDL-C are necessary to prevent CHD events (3-5).

However, the convincing epidemiologic data linking HDL-C and CHD
risk has not yet translated into significant clinical trial evidence
supporting linearity between HDL-C increases and CHD risk reduction.
The recent negative results obtained in the ILLUMINATE and AIM-HIGH
trials suggest that HDL-C increases may not always be beneficial (41,
63). The results from these studies have led us to more questions than
answers in our quest to reduce CHD events by improving HDL-C.

HDL FUNCTION
The knowledge of an inverse relationship between plasma levels of
HDL-C and rates of CHD gained from epidemiological studies has long
been held as a near guarantee that interventions that increase HDL-C
will reduce CHD risk (6, 7). However, investigators in clinical trials have
so far failed to convey a mandate to increase HDL-C levels by a specific
degree or beyond a specific threshold to achieve protection against
CHD events (8). Moreover, both genetic studies and clinical trials
support the idea that, in some circumstances, HDL-C levels may
behave opposite to what is predicted by the Framingham assessment
model (9, 10). For example, carriers of the apoAI Milano mutation
present with low levels of HDL-C but are resistant to
atherosclerosis(11,12), whereas subjects with cholesteryl ester transfer
protein (CETP) deficiency have high HDL-C levels but are not patently

protected against atherosclerosis(13-16). In addition, common
polymorphisms in the CETP and hepatic lipase genes linked to elevated
HDL-C levels are associated with increased cardiovascular events (17,
18).

These apparently contradictory findings may be explained by the
notion that a ‘‘functional’’ HDL, rather than high plasma HDL-C
concentration, is needed for a therapeutic effect. HDL functionality and
HDL-C concentrations likely go hand in hand in most people, but may
diverge in the presence of specific mutations, in some disease states,
or by the action of drugs (19-21). Therefore, newer therapies need to
target HDL functionality rather than only HDL-C concentrations in the
blood.

Mutations affecting the function of an enzyme rarely are linked to
improved metabolism or health. Polymorphisms of both the CETP gene,
leading to high HDL-C levels through reduced cholesterol exchange,
and the hepatic lipase gene, leading to high HDL-C levels through
impaired lipolysis, have been linked to increased risk for CHD (17, 18).
Indeed, a dysfunctional HDL is more likely associated with high, rather
than low, HDL-C levels because it may often reflect altered recycling of
the mature plasma HDL particle. Because of its high concentration,
carrying a dysfunctional HDL may be more dangerous for vascular

health than having low levels of functional HDL. Ansell et al (22)
showed that patients with CHD and HDL-C greater than 85 mg/dL carry
dysfunctional HDL. A recent analysis of The Incremental Decrease in
Endpoints through Aggressive Lipid Lowering trial (IDEAL) and
European Prospective Investigation of Cancer-Norfolk observational
study determined that the classic inverse correlation between HDL-C
and CHD risk is not sustained when evaluating subjects with HDL
greater than 70 mg/dL who appear to have increased CHD risk even
when on statin therapy (23). CHD risk was also increased by the
presence of large HDL particles, suggesting that dysfunctional reverse
cholesterol transport with accumulation of lipid-loaded HDL in the
plasma and high HDL-C levels is a pro-atherogenic condition (23). Thus
it is becoming clear that a functional HDL is a more desirable target
than simply increasing HDL-C levels.

A reason why so much emphasis is placed on the plasma HDL-C level
as a predictor of vascular health is because it theoretically represents
reverse cholesterol transport
(RCT), the system in charge of removing cellular cholesterol excesses
from tissue sites of accumulation (24). The sub endothelial space of the
medium caliber artery is the most important tissue in this regard
because accumulation of cholesterol-rich cells causes atheroma
formation and the real target of therapy is to activate cholesterol exit

from this very site. Because the essential function of HDL occurs in the
extravascular space, and not in the plasma compartment, it is likely
that plasma HDL-C levels have a limited power to predict RCT
functionality in the target tissue. Moreover, HDL influences the
atherogenic process not only through cholesterol extraction but also
through anti-inflammatory and antioxidant properties (25).

However, what we test in plasma is almost exclusively the amount of
cholesterol that the HDL has collected from tissues other than the
arterial wall. If inappropriate amounts of HDL penetrate the plaque or if
the load of oxidized plaque lipids destabilizes HDL function, it is
obvious that plasma HDL-C levels may be more and more disconnected
from CV risk prediction. This new knowledge on dysfunctional HDL has
been termed a paradox because functionality is not directly linked to
changes in HDL-C plasma concentrations (26). However, there is
nothing paradoxical about it. RCT is necessary to remove excess
cholesterol from peripheral cells in all tissues, a biologically essential
function even if cholesterol trapping in the artery wall and the
atherosclerotic process were not a common occurrence in humans.
Plasma HDL-C levels represent the balance between generation of
mature HDL particles in the circulation and loss of lipid cargo via both
HDL receptor (scavenger receptor type BI [SR-BI])-mediated transfer to
hepatocytes and CETP-mediated transfer to other lipoproteins.(27,28)

Loss of lipid cargo is a desirable event because it leads to unloading of
cholesterol and oxidized phospholipids in the liver and to the rebirth of
the HDL particle for a new round of cholesterol acquisition. Therefore, a
high HDL-C level may mean enhanced production of mature HDL in the
plasma compartment (a good thing) or reduced loss of lipid cargo (not
a good thing). Conversely, a low HDL-C level may signal increased loss
of lipid cargo (a good thing) or reduced peripheral cholesterol
collection (not a good thing).

HDL METABOLISM
HDL starts its life cycle as poorly lipidated apolipoprotein A1 (apoAI),
which has a mandate to collect cellular cholesterol to avoid
receptor-mediated degradation in the renal tubule (29, 30) (see Fig 1).
ApoAI collects membrane cholesterol through multiple mechanisms,
including specific ones requiring physical engagement with
transmembrane lipid channels such as ATP-binding cassette
transporter A1 (ABCA1), ATP-binding cassette transporter G1 (ABCG1)
and scavenger receptor class B member (SR-BI) (31). It is believed that
ABCA1 transfers phospholipids and cholesterol to the nascent HDL
(32), whereas ABCG1 connects with larger HDL particles (33). SR-BI
(also known as the hepatic HDL receptor) contributes significantly to
lipid transfer from cells overloaded with cholesterol, such as arterial

macrophages, and therefore may play a central role in atherogenesis
(34). As free (unesterified) cholesterol translocates across the cell
membrane, HDL esterifies it by adding a fatty acid chain via the action
of lecithin cholesterol acyl-transferase (LCAT) (31). The nonpolar
cholesteryl esters are then stored in the particle core. The core
expansion leads to compositional maturation, yielding particles that
predominate in plasma HDL. This sequence of changes means that
HDL is heterogeneous in size because of variations in total lipid cargo
and in the array of lipoproteins, enzymes, and other functional proteins
that can exist on its surface (35).
In the plasma compartment the mandate of the mature HDL switches
from cholesterol acquisition to cholesterol delivery. This is achieved
mainly via cholesteryl ester transfer protein (CETP)-mediated transfer
of cholesterol to triglyceride-rich lipoproteins and via SR-BI mediated
unloading of the cholesterol cargo in the liver. Plasma HDL that
eliminates its lipid cargo can initiate a new cycle of peripheral
cholesterol acquisition. This ‘‘reverse cholesterol transport-centric’’
view of HDL also encompasses the notion that its powerful anti-oxidant
and anti-inflammatory effects are linked to the collection and removal
of oxidized lipids from both cellular membranes and LDL in the arterial
wall (36).

NONPHARMACOLOGIC APPROACHES FOR RAISING HDL

The National Cholesterol Education Program (NCEP) Adult Treatment
Panel III (ATP III) increased the definition of low HDL cholesterol from
35mg/dl to 40mg/dl (37). Low HDL-C is also an important component of
the definition for metabolic syndrome, with cut points of 40mg/dl for
men and 50mg/dl for women. The NCEP ATP III guidelines state that
therapeutic lifestyle changes are the initial intervention for increasing
HDL cholesterol. These therapeutic lifestyle change measures include
reducing the dietary intake of cholesterol, increasing the use of plant
stanols/sterols and fiber to lower LDL cholesterol, and moderating
intake of calories and increasing physical activity to maintain desirable
weight and cardiovascular fitness. Weight loss and smoking cessation
are also advocated and can aid in raising serum levels of HDL. Dietary
modification, including ingestion of omega-3 fatty acids via fish
consumption or fish oil supplementation, has also demonstrated an
effect in raising HDL-C. When therapeutic lifestyle changes are not
adequate to increase serum HDL-C, pharmacologic therapy is often
recommended.

PHARMACOLOGIC THERAPY
When therapeutic lifestyle changes are not adequate to achieve target
goals, several pharmacologic therapy options exist for the
management of low HDL-C (Table 1). It is well established that
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase

inhibitors (statins) lower LDL-C, which significantly affects
cardiovascular morbidity and mortality (2). Other non-LDL lipid effects
of statins, including decreasing triglycerides and raising HDL-C, may
also contribute to the risk reduction. Additional therapies with
significant LDL lowering effects, such as fibrates and niacin, which
lower triglycerides and raise HDL-C, also have been shown to reduce
CHD events despite less potent effects on reducing LDL (38). As
highlighted in the NCEP ATP III guidelines, consideration should be
given to combination therapy with a fibrate or nicotinic acid in addition
to a statin for high-risk patients with a low HDL-C level (see Fig 2).

STATIN THERAPY
First-line management of dyslipidemia in patients with cardiovascular
disease is achieved with statin therapy. In patients with low HDL-C,
statins are very effective in reducing the absolute cardiovascular event
rate (2). However, the residual risk of CHD events remains high. Statins
typically increase HDL-C levels by approximately 5% to 10%. Although
the mechanism(s) by which statins raise HDL-C remains unclear,
statins appear to reduce the supranormal rates of endogenous
CETP-mediated cholesteryl ester transfer from HDL by decreasing the
number of Apo B lipoprotein available to accept cholesteryl ester from
HDL. Statins also appear to enhance hepatic Apo AI production, which
may not occur with high-dose atorvastatin (80 mg) in which there is

less HDL-C increase compared with similar LDL-C lowering by
simvastatin or rosuvastatin. The clinical relevance of the difference in
the HDL-C increase between atorvastatin 80 mg and rosuvastatin 40
mg is being tested in the Study of Coronary Atheroma by Intravascular
Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN) trial,
an intravascular ultrasound (IVUS) trial measuring plaque volume in
CHD patients (39).

NIACIN
Niacin, or nicotinic acid, is a soluble B vitamin that has favorable
effects on all major lipid sub fractions but has limited use due to its
side-effect profile. Niacin was one of the first lipid-altering drugs to
demonstrate a reduction in CHD events in the Coronary Drug Project
(40). At present, niacin is identified as the most effective approved for
raising HDL-C. In clinical studies, niacin has been demonstrated to
lower LDL by 10% to 20%, triglyceride (TG) by 20% to 40%, and Lp (a)
by 10% to 30%, as well as raise HDL by 15% to 30% (40). Niacin
appears to increase HDL-C by decreasing the hepatic uptake of Apo AI,
thereby delaying catabolism (41). Despite niacin being widely used in
the management of dyslipidemia, the side effect of flushing of the face
and upper body can affect compliance to therapy. Flushing has been
attributed as the major reason for discontinuation of therapy,
estimated at rates as high as 25% to 40%The flushing that is induced

by niacin is caused by the subcutaneous release of prostaglandin D2
(PGD2), which is mediated by niacin’s action as a pharmacologic ligand
for the adipocyte and macrophage G protein coupled nicotinic acid
receptor, GPR109A (42). The cutaneous vasodilation skin flush typically
starts in the face with a deep red coloration, usually accompanied by
an intense feeling of warmth and itching, with occasional extension to
the arms and chest. Although the duration of the flushing is generally
less than 1 hour, the unpleasant sensation for patients can often affect
compliance and lead to therapy discontinuation. Moderate doses of
prostaglandin inhibitors have been demonstrated to reduce the
cutaneous flushing response from niacin (43). Several additional
strategies for reducing niacin induced flushing include regular
consistent dosing, use of extended-release formulations, patient
education, dosing with meals or at bedtime, and avoidance of alcohol,
hot beverages, spicy foods, and hot baths or showers close to or after
dosing. In comparison with immediate release niacin, extended-release
niacin results in reduced flushing as it is taken once a day at bedtime,
when most flushing symptoms will occur when the patient is sleeping.
However, the side effect profile includes the potential for liver toxicity
(44). Other side effects include rash, flushing, gastrointestinal
problems, worsening of esophageal reflux and gout, and headache
(44).

STATIN – NIACIN COMBINATION THERAPY
Combination therapy with a statin and niacin has been used to reduce
residual cardiovascular risk after statin use by targeting both the
lowering of LDL-C and increasing low HDL-C. Several clinical trials using
either immediate-release or extended-release niacin have
demonstrated the efficacy and safety of this combination therapy in
inhibiting the development of atherosclerosis (45). The Arterial Biology
for the Investigation of the Treatment Effects of Reducing Cholesterol
(ARBITER) 2 trial demonstrated that the addition of extended-release
niacin to statin therapy resulted in an increase in HDL-C of 21% and
slowed the progression of atherosclerosis as measured by a change in
carotid intima-media thickness (CIMT), as compared with statin therapy
alone in patients with known CHD and low HDL-C levels (45). Although
the ARBITER 2 trial showed slowing of progression of atherosclerosis,
whether this translates to reduction of CHD events remains unclear.

The Atherothrombosis Intervention in Metabolic Syndrome with Low
HDL/High Triglycerides: Impact on Global Health (AIM-HIGH) trial was
the first large-scale outcomes study to evaluate the impact of adding
extended-release niacin to statin therapy (simvastatin) in patients with
established coronary artery disease (46). The study was designed to

test whether or not increasing HDL-C and lowering triglycerides in
patients with low HDL-C and high triglycerides will reduce the risk of
recurrent cardiovascular events in patients whose LDL-C was already
within a desirable range with statin therapy.

AIM-HIGH enrolled 3414 participants in the US and Canada , who were
all prescribed simvastatin and then randomized to either high-dose,
extended-release niacin in gradually increasing doses up to 2000 mg
per day (n=1718) or placebo (n=1696). Of the participants, 515 were
given a second LDL-cholesterol–lowering drug, ezetimibe (Zetia,
Merck/Schering-Plough), in order to maintain LDL-cholesterol levels at
the target range between 40 and 80 mg/dL.
The primary end point for AIM-HIGH was a composite defined as time
to first occurrence of any of the following: fatal or nonfatal myocardial
infarction, ischemic strokes, hospitalizations for acute coronary
syndrome or symptom driven coronary or cerebral revascularization
procedures. Background therapy for all risk factors (blood pressure,
blood glucose) was rigorous and met the goals set forth in the
guidelines for high-risk patients. The addition of niacin to half of the
patients did provide incremental HDL-C elevation and triglyceride
reduction. However, the National Heart, Lung, and Blood Institute
halted the trial prematurely because continuing was deemed futile
after interim analyses showed no significant difference in adverse

outcomes between the two groups (249 primary outcome events [15%]
in the simvastatin arm and 262 [15%] in the simvastatin/niacin arm;
hazard ratio 1.053, 97.5% CI: 0.885-1.252; P=0.561). Moreover,
investigators observed an excess hazard for ischemic stroke (28 vs. 12)
that was numerically, though not statistically, significant in the group
receiving niacin. Because of the small difference between treatment
arms and the early termination of the trial, AIM-HIGH was
underpowered to prove the hypothesis that niacin therapy may be
beneficial in a secondary prevention population with controlled LDL-C.
Therefore, the results of the study cannot be extrapolated to all
patients with low HDL or all patients with uncontrolled LDL. The
findings of AIM-HIGH will require careful study to determine if there are
specific reasons for the failure of niacin to provide incremental risk
reduction in this population of patients. The entire question of
emerging science related to modulation of HDL in blood plasma is still
being evaluated as new therapies beyond niacin are being developed.
Ongoing pharmaceutical outcomes studies such as HPS2-THRIVE with
over 25,000 patients may provide more insight regarding the efficacy
of niacin in combination with statins to reduce CHD events.
The Heart Protection Study 2 Treatment of HDL to Reduce the
Incidence of Vascular Events (HPS-2-THRIVE) is another large
international trial of high-dose, extended-release niacin with
simvastatin alone or in combination with ezetimibe in patients with

established cardiovascular disease. The study is still ongoing, with
results expected in 2013 (47)

STATIN-FIBRATE COMBINATION THERAPY
Statin-fibrate combination therapy is effective in reducing LDL-C and
TG, and in increasing HDL-C. Fibrates are peroxisome
proliferator-activated receptor-alpha (PPAR-a) ligands that lead to
increased lipoprotein lipase expression and decreased Apo CIII
expression. This results in enhanced catabolism of TG-rich particles.
The expression of Apo AI and A-II are also increased by fibrates, with a
net result of decreasing hypertriglyceridemia and increasing HDL-C.
Due to these effects, fibrate combination therapy is used for patients
with hypertriglyceridemia and low HDL. Statin- fibrate combination use
is restricted, due to reports of rhabdomyolysis that mainly involved
gemfibrozil and cerivastatin, which was voluntarily withdrawn from the
market worldwide in 2001 after reports of fatal rhabdomyolysis.

Fenofibrate or fenofibric acid is the fibrate of choice when used in
combination with a statin because each is associated with a lower risk
of myopathy than gemfibrozil. Several recent studies have
demonstrated the efficacy and safety of fenofibric acid and statin

therapy in patients with mixed dyslipidemia in reducing triglycerides
and raising HDL-C compared with statin monotherapy.

NOVEL HDL-C DIRECTED THERAPEUTIC STRATEGIES
There are four different therapeutic approaches to improve HDL-C (see
Table 2):
1. Directly augmenting the concentration of apolipoprotein A-I (apo
A-I), the major protein constituent of HDL
2. Indirectly augmenting the concentration of apo A-I and HDL-C
3. Mimicking the functionality of apo A-I
4. Enhancing reverse cholesterol transport.

1. Directly Augmenting Apo A-I Levels
Recombinant HDL: Lipid-poor apo A-I, also termed nascent HDL or
preβ-HDL, initiates reverse cholesterol transport by activating
macrophage (ABCA1) and accepting effluxed cholesterol. From a
pharmacodynamic standpoint, direct augmentation of lipid-poor apo A-I
concentration arguably represents the most validated HDL-related
therapeutic approach in terms of anti-atherogenic potential.

Lipid-poor apo A-I–phospholipid complexes, sometimes referred to as
recombinant HDL (rHDL), have been studied extensively in animals and

in preliminary studies in humans. Preclinical studies have
demonstrated that the administration of apo A-I is associated with the
inhibition or regression of atherosclerosis (51-54), enhanced
macrophage-specific reverse cholesterol transport (55) and the inhibition of vascular inflammatory pathways (56). Moreover, short
exploratory clinical studies of rHDL infusion have yielded decreases in
coronary atherosclerosis, as assessed by coronary imaging, comparable with those obtained with long-term statin use at doses
associated with improved clinical outcomes. These findings support the
therapeutic potential of intravenous apo A-I infusion (57, 58).

ApoA-1 Milano: The apo A-I Milano mutation was first identified in a
cohort of Italian patients who exhibited a decreased prevalence of
atherosclerosis despite very low levels of HDL-C (10–20 mg/dl) (53).
The effects of apo A-I Milano complexed with phospholipid
(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), also known as
ETC-216, have been studied in animals and humans (58). In support of
an anti-atherogenic activity, infusions of ETC-216 in rabbit and mouse
models of atherosclerosis were associated with considerable reductions
in the lipid and macrophage content of plaque (60-62).

In a small clinical study of 47 patients with acute coronary syndrome,
five weekly doses of 15–45 mg/kg of ETC-216 significantly reduced

total atheroma volume by 14.1 mm3 compared with baseline (4.2%; P
<0.001), as measured by coronary intravascular ultrasonography
(IVUS) (58) . Total atheroma volume did not change significantly with
the administration of placebo (–0.2 mm3; P = 0.97).

Wild type Apo A-I: Human plasma derived wild-type apoA-1 linked to
soybean phospholipid (CSL111) was infused at 40 mg/kg per infusion in
humans in a small proof of concept trial (63). Five weekly infusions did
not show a significant benefit on coronary plaque progression in
comparison with placebo. However, when compared with pretreatment
baseline, apoA-1 recipients showed regression in contradistinction to
the placebo arm (63). The 80 mg/kg per infusion regimen was
abandoned because of hepatic toxicity even though a single infusion of
80 mg/kg, in an unrelated study, was shown to favorably change
femoral artery plaque composition (64). Overall, short-term infusion of
synthetic HDL (containing apo A-I Milano or wild-type apoA-1) holds
considerable promise as a potential strategy for rapid plaque
remodeling and stabilization that could later be sustained with the use
of orally LDL-C lowering and HDL-C raising agents, or even possibly
repeated infusions. However, this requires further study.

Autologous Delipidated HDL: Another novel technique for
increasing HDL-C involves the collection of 1 L of plasma by apheresis.

The technique includes over 2 hours of apheresis followed by selective
lipid removed from HDL using organic solvents to produce lipid-poor
pre-b HDL. The lipid-poor pre-b HDL, which is a more efficient acceptor
of cholesterol, is then reinfused back into the patient. In a small human
trial involving 28 patients with acute coronary syndrome, 7 weekly
treatments resulted in a 5.2% decrease in atheroma volume compared
with baseline (65). Small clinical trials using intravascular ultrasound of
the coronary arteries showed a similar 3.5% to 5% decrease in
atheroma volume compared with baseline, but due to the small sample
sizes were not statistically significantly different from placebo.

2. Indirectly Augmenting Apo A-1 Levels
Oral Upregulator of Endogenous Apo A-1: RVX-208, an oral
upregulator of endogenous Apo A-1 selectively induces nuclear
transporter factors which in turn induces hepatic and intestinal
production of Apo AI. This compound significantly increases HDL-C by
more than 40% in monkeys, and the serum of treated animals was
shown to enhance cholesterol efflux from foam cells (66). Significant
increases in total plasma Apo AI were demonstrated in a small
short-term human trial, but most of the increase was in pre-b HDL.
RVX-208 was the first oral small molecule that stimulates Apo AI
production to enter phase 2 trials.

Niacin Receptor Agonists
Niacin, the first antidyslipidemic agent identified, remains the most
potent drug in use for increasing levels of HDL-C and apo A-I. However,
the side effect of flushing of the face and upper body reduces
compliance and leads to discontinuation of therapy in up to 25% to
40% of patients (44).The discovery of the niacin receptor GPR109A90
promised to usher in a new era in which the molecular mechanisms
underlying the effects of niacin on lipids, and its adverse effects could
be clearly defined (67). Co administration of the DP1 antagonist
laropiprant reduces the incidence of the skin-related adverse effects of
niacin (68). However, flushing still occurs in over half of the patients,
and discontinuation of niacin treatment owing to severe skin-related
symptoms remains a problem (69). A study in mice implicated
keratinocyte-produced prostaglandin, PGE2 as a key mediator of
niacin-induced skin flushing, suggesting that this molecule might be
another potential target to minimize flushing (70, 71).

3. Mimicking Apo A-I Functionality
Another HDL-directed therapeutic approach utilizes small peptides that
mimic one or more of the functions of apo A-I (72, 73). The most
well-studied apo A-I mimetic, 4F, consists of 18 amino acids designed
to share the lipid-binding properties of apo A-I through a common
secondary structure, the class A amphipathic helix (74). The only

reported human study of D-4F to date hints at the possibility of a
benefit for this compound in humans (75). Compared with HDL isolated
from individuals who received placebo, HDL isolated from individuals
treated with a single 300 mg or 500 mg dose of unformulated D-4F
increased the inhibition of LDL-induced monocyte chemotaxis in
cultures of human aortic endothelial cells. As in animal studies, neither
changes in apo A-I or HDL-C levels nor serious toxicity were observed
in treated individuals.

4. Enhancing reverse cholesterol transport
CETP Inhibitors
CETP plays an important role in cholesterol metabolism, as it is
responsible for the transfer of cholesteryl esters from HDL-C to VLDL-C
and LDL-C (see Figure 1). CETP is a very large protein and has a
hydrophobic tunnel across the molecule that can accommodate neutral
lipid. CETP is a shuttle-type structure that promotes an equal mass
gradient transfer of triglyceride for cholesterol ester between HDL and
Apo-B lipoprotein (76). CETP plays an important role in maintaining a
uniform distribution throughout the bloodstream and moves
triglycerides where they are high (i.e., VLDL-C) to where they are low
(HDL-C and LDL-C) in exchange for an equal mass gradient of
cholesterol ester. Animals that lack CETP have very high HDL-C and
very low LDL-C. CETP is important in modulating HDL size by

redistributing cholesterol ester from triglyceride-rich particles into HDL
particle. The triglyceride-enriched HDL is further acted on by hepatic
lipase to form a smaller dense HDL that is more rapidly catabolized.

CETP is also involved in transporting triglycerides in exchange for
cholesterol ester from triglyceride-rich particles to LDL. LDL becomes
triglyceride enriched and further hydrolyzed by the lipases to form a
small dense atherogenic LDL. Theoretically inhibition of CETP should
therefore result in beneficial effects on HDL-C and LDL-C which could
translate into decreased atherogenesis and reduced cardiovascular
events.

In the Investigation of Lipid Level Management to Understand its
Impact in Atherosclerotic Events (ILLUMINATE) which involved patients
receiving atorvastatin were randomized to torcetrapib or placebo (77).
Torcetrapib worsened the primary combined cardiovascular end point
of death from coronary heart disease, nonfatal myocardial infarction,
stroke, and hospitalization for unstable angina (hazard ratio [HR] 1.25,
95% CI 1.09–1.44, P = 0.001) as well as all-cause mortality (HR 1.58,
95% CI 1.14–2.19, P = 0.006) compared with placebo after 12 months.
This was despite torcetrapib increasing HDL-C by 72% and decreasing
LDL-C by 25%. The worrisome results of ILLUMINATE were paralleled by
negative imaging findings in trials in which coronary and carotid

ultrasonography were used (78, 79). These negative findings have
been at least partly attributed to the off-target effects of torcetrapib,
such as the raising of systolic blood pressure by an average of 5.4
mmHg. As suggested by aldosterone measurements from participants
in ILLUMINATE (77), findings from animal models (80) and human
adrenal cell assays (81) suggest these off-target effects may be related
to stimulation of aldosterone synthesis by torcetrapib via pathways
independent of CETP inhibition.

Could inhibition of CETP activity explain some of the adverse effects
observed in the clinical development program of torcetrapib? Initial
concerns about CETP inhibition highlighted the possibility that the
formation of large cholesterol-rich HDL particles resulting from CETP
inhibition might be associated with impaired cholesterol efflux from
peripheral macrophages to these particles (82). However, studies of
patients either deficient in CETP or treated with a CETP inhibitor
demonstrated not reduced, but rather enhanced, efflux of cholesterol
via ABCG1 to HDL-C (83, 84). Thus, an important step of reverse
cholesterol transport remains intact, if not improved, in the setting of
CETP inhibition.

On the other hand, the net effect of CETP inhibition on reverse
cholesterol transport might depend, in part, on the effects of CETP on

the hepatic uptake of HDL-derived cholesterol. The hepatic uptake of
HDL-C can be direct, or occur after transfer of HDL-C via CETP to apo
B-containing lipoproteins, which are then taken into the liver via the
LDL receptor. As illustrated by macrophage-specific reverse cholesterol
transport assays, in the setting of highly effective LDL clearance, CETP
can actually enhance reverse cholesterol transport and have an
atheroprotective role. However, when LDL clearance is impaired, CETP
can

slow

down

proatherogenic

reverse

(85).

The

cholesterol

transport

interdependence

of

and
terminal

thus

be

reverse

cholesterol transport pathways suggests that individuals who are most
likely to benefit from CETP inhibition are those with suboptimal
LDL-receptor-mediated hepatic uptake of cholesterol.

Fortunately, at least two novel compounds apparently lacking the
off-target

effects

of

torcetrapib

enable

further

testing

of

the

CETP-inhibition strategy, namely dalcetrapib and anacetrapib.

Dalcetrapib: Dalcetrapib binds CETP irreversibly and is considerably
less-potent than torcetrapib (86). A study in a hamster model
suggested that dalcetrapib promotes reverse cholesterol transport
(87). In a human study, among individuals with mean baseline HDL-C
and LDL-C levels of 47 mg/dl and 144 mg/dl, respectively, monotherapy with 600 mg of dalcetrapib daily increased HDL-cholesterol

levels by 23% compared with placebo administration, after 4 weeks of
treatment (88). Among patients with type II dyslipidemia receiving 40
mg of pravastatin daily and whose baseline levels of HDL-C and LDL-C
were 48 mg/dl and 120 mg/dl, respectively, the addition of 600 mg of
dalcetrapib daily increased HDL-cholesterol levels by 28% and
decreased LDL-cholesterol levels by 7% compared with placebo
administration, after 4 weeks of treatment (89). After 24 weeks of
therapy with 900 mg of dalcetrapib daily, HDL-C levels increased by
33% (mean baseline level of 42 mg/dl) in patients at high risk of
coronary heart disease events who were treated with 10–80 mg of
atorvastatin daily, when compared with HDL levels in participants
receiving placebo plus atorvastatin (90). LDL-C levels, however, did not
differ in the two patient groups (mean baseline level of 74 mg/dl).
Importantly, no changes in blood pressure or aldosterone levels were
observed with the use of high-dose dalcetrapib (900 mg).

Dal-PLAQUE (91) was a phase IIb, double-blind trial conducted at 11
centers in patients with CHD or CHD risk equivalents, treated with
LDL-C lowering drugs to LDL-C <100 mg/dL (<2.6 mmol/L). Patients
were randomized to dalcetrapib 600 mg or placebo daily for 24
months, with a 2-week safety follow-up. Endpoints included indices of
plaque burden from the right and left carotid and abdominal aorta
determined by magnetic resonance imaging (MRI) after 24 months,

and plaque inflammation using 18F-fluoro-deoxyglucose uptake
measured by positron emission tomography/computed tomography
(PET/CT) after 6 months. 189 subjects were screened and 130
randomized into the trial. Based on MRI, a significant reduction in total
vessel area and a trend towards reduction in average wall area were
observed with dalcetrapib vs. placebo after 24 months (-4.01 mm2
[-7.23, -0.80]; p=0.041 and -2.20 mm2 [-4.54, 0.13]; p=0.120
respectively). Other indices of plaque burden were numerically reduced
from baseline with dalcetrapib versus placebo. Based on PET/CT, mean
of maximum standardized uptake value and target to background ratio
were unchanged with dalcetrapib versus placebo after 6 months.
HDL-C increased by 31% with dalcetrapib after 24 months with no
significant increases in inflammatory biomarkers. Dalcetrapib was well
tolerated with a safety profile similar to placebo and was not
associated with an increase in blood pressure.

Dal-PLAQUE 2 (92) will also assess changes in atherosclerotic plaque
(morphology, composition, and inflammatory activity) among patients
with CHD treated with 600 mg of dalcetrapib daily.

Dal-VESSEL (93) was an exploratory phase IIb randomized,
double-blind, placebo-controlled trial in patients with CHD or CHD risk
equivalents, in which 476 patients with HDL-C levels <50 mg/dL were

recruited. They received dalcetrapib 600 mg/day or placebo in addition
to their existing treatments. The primary efficacy endpoint was change
from baseline in brachial flow mediated dilation after 12 weeks. The
primary safety endpoint was 24-hour ambulatory blood pressure
monitoring assessed at week four. Patients were treated for a total
period of 36 weeks. Results showed that dalcetrapib reduced CETP
activity by almost 50% and increased HDL-C levels by 31% without
changing nitric-oxide-dependent endothelial function or markers of
inflammation and oxidative stress. Dalcetrapib did not increase
24-hour ambulatory blood pressure (ABPM) at week 4, the primary
safety endpoint.

Finally, the phase III clinical trial Dal-Outcomes (94) will evaluate the
effects of adding 600 mg of dalcetrapib daily to optimum
pharmacotherapy in patients with acute coronary syndrome over a 2
year follow up period, with results expected in 2013.

Anacetrapib: Anacetrapib inhibits CETP by forming a tight reversible
bond (95). Healthy individuals with mean baseline HDL-C and LDL-C of
51 mg/dl and 138 mg/dl, respectively after receiving 300 mg of
anacetrapib daily for 10 days showed increases in HDL-C by 129% and
decreases in LDL-C by 38% (96). No changes in blood pressure,
assessed through 24 h ambulatory monitoring, were observed. Among

patients with dyslipidemia who had mean baseline HDL-C and LDL-C of
50 mg/dl and 141 mg/dl, respectively, addition of 300 mg of
anacetrapib to 20 mg of atorvastatin daily for 8 weeks increased HDL-C
by 120% and decreased LDL-C by 30% compared with statin
monotherapy (97). Interestingly, lipoprotein (a) levels, which were
unchanged by statin therapy, decreased by 50% following anacetrapib
administration.

The phase III Determining the Efficacy and Tolerability of CETP
Inhibition with Anacetrapib (DEFINE) randomized, placebo-controlled
trial examined the effect of 100 mg of anacetrapib administered daily
for 18 months to 1623 CHD or CHD equivalent patients who had
achieved LDL-C treatment goals with statin therapy(98). The primary
end points were the percent change in LDL-C at 24 weeks and the
safety profile of anacetrapib at 76 weeks. HDL-C and other lipid
parameters including lipoprotein (a) were assessed as secondary
endpoints (94). Treatment with anacetrapib was associated with a 40%
reduction in LDL-C from 81 mg/dl to 45 mg/dl (P <0.001) and a 138%
increase in HDL-C from 41 mg/dl to 101 mg/dl (P <0.001) compared
with placebo. Lipoprotein (a) decreased 36% compared with placebo
from 27 nmol/l to 15 nmol/l. No increases in clinic-based blood
pressure, serum aldosterone levels, or cardiovascular events were
observed following anacetrapib treatment at 76 weeks. Supported by

these substantial improvements in LDL-C, HDL-C, and lipoprotein (a),
as well as an apparently benign safety profile, the Randomized
EValuation of the Effects of Anacetrapib Through Lipid-modification
(REVEAL) is scheduled to begin in April 2011(100). This study will
examine major coronary events in 30,000 patients with coronary heart
disease, cerebrovascular atherosclerotic disease, or peripheral artery
disease (see Table 3).

Agonists of the Liver X Receptor
Liver X receptors (LXRs), which are members of the nuclear receptor
superfamily, have a central role in lipid metabolism. Endogeneously
activated by oxysterols, LXRs regulate the transcription of a myriad of
target genes by binding to their promoters together with the retinoic
acid receptor (101). With regard to HDL and reverse cholesterol
transport, LXR activation has been demonstrated to promote
mobilization of intracellular cholesterol (102), increase macrophage
cholesterol efflux via macrophage ABCA1 and ABCG1 (103), and
augment intestinal HDL generation (104).Therapeutic development of
LXR agonists has been hindered by hepatic steatosis and increased
plasma triglyceride concentrations reported in preclinical studies of
these drugs (105).

Endothelial lipase inhibitors

Synthesized by and bound to vascular endothelial cells, endothelial
lipase exhibits predominant phospholipase activity and affinity for HDL,
unique characteristics among the lipoprotein–lipase family (106). An
association between the expression of endothelial lipase and
HDL-cholesterol levels was identified in overexpression and
loss-of-function mouse models (107-109).Genetic studies indicate a
similar association in humans, with rare and low-frequency
loss-of-function variants of endothelial lipase, identified through deep
sequencing, resulting in elevated HDL-cholesterol levels (110). How
changes in HDL-cholesterol levels attributed to endothelial lipase
ultimately affect atherosclerosis remains uncertain. Some human
studies point to an atherogenic role of endothelial lipase, with a
positive association between plasma levels of this enzyme and
coronary artery calcification, features of the metabolic syndrome (such
as impaired fasting glucose, and waist circumference), and
inflammation (111,112). Carriers of endothelial-lipase variants
associated with raised HDL-cholesterol levels have been reported to
have a decreased risk of atherothrombotic disease,(113) although this
link has not been observed in other studies (114,115). Of note, animal
studies have shown that HDL-cholesterol levels do not always correlate
with physiological changes associated with decreased atherosclerotic
burden, with an endothelial-lipase knockout mouse model failing to
demonstrate improved macrophage reverse cholesterol transport with

raised HDL-cholesterol levels (116). More worrisome, in the setting of
hepatic-lipase deficiency, is that the absence of endothelial lipase
resulted in an accumulation of small dense LDL,(116) a particularly
atherogenic subpopulation of LDL. These findings suggest that
endothelial-lipase inhibition could potentially exert a detrimental effect
on atherosclerosis, even though HDL-cholesterol levels are raised.
Despite this uncertainty, endothelial lipase has been the object of
substantial interest as a therapeutic target. High-throughput screening
identified several compounds sharing a sulfonyl furan urea core as
potent and selective endothelial-lipase inhibitors (117). Further
evaluation of these and other small-molecule inhibitors of endothelial
lipase has not been performed yet.

Conclusions
Targeting HDL-C is an integral component of the management of CHD
and risk reduction. Several strategies can be used to increase HDL-C
levels to target cardiovascular risk reduction, including pharmacologic
management focused on the use of statin, statin combination therapy,
and investigational drugs targeting HDL-C metabolism and reverse
cholesterol transport. However, the negative results obtained from the
ILLUMINATE and AIM-HIGH clinical trials suggest that improving HDL-C
levels in plasma alone does not necessarily translate into
cardiovascular risk reduction. Due to the complexity of HDL cholesterol

metabolism and the wide variety of targets for improving HDL
cholesterol levels, it is clear that further research is needed to
determine which will be the safest, most cost-effective, and most
efficacious for reducing both rates of atherogenesis and risk for acute
cardiovascular events. Ongoing and future clinical trials will
comprehensively evaluate these HDL cholesterol–raising therapies in
patients in both the primary and secondary prevention settings.
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Table 1: Traditional drug therapy used to increase HDL-C
Drug

HDL-C

Class
Statins

Increase
5%-15%

Mechanism of Action

Side Effects

Clinical Trial

3-hydroxy-3-methyl-

Myopathy,

Results
Reduced major

glutaryl-CoA

Increased

coronary events,

reductase

liver

CAD deaths,

(HMG-CoA) inhibitor

enzymes.

need for
coronary
procedures,
stroke and total

Niacin

15%-35%

Decreased

Flushing,

mortality
Reduced major

clearance of ApoA1

hepatotoxicit

coronary events

y,
hyperuricemi
a, upper
gastrointestin
al distress,
hyperglycemi
Fibrates

10%-20%

Peroxisome

a
Dyspepsia,

Reduced major

proliferator-

gallstones,

coronary events

activated

myopathy

receptor-alpha
(PPAR-α) agonist

Table 2:HDL- directed pharmacotherapeutic strategies
Directly augmenting apo A-1
Intravenous apo A-1 therapy
• Recombinant apoA-1 Milano/phospholipids (ETC-216)
• Purified native apoA-1/phospholipids (CSL-111/112)
• Autologous delipidated HDL
Indirectly augmenting apo A-1
• Oral upregulator of endogenous apoA-1 production (RVX-208)
• Niacin receptor (GPR109A) agonists
Mimicking Apo A1 Functionality
• Apo A-1 mimetic peptides
Enhancing reverse cholesterol transport
Cholesterol ester transfer protein inhibitors
• Dalcetrapib
• Anacetrapib
Liver X receptor agonists

Table 3: Ongoing late-stage clinical trials of HDL-directed therapies
Drug

Trial

Patient population (n)

Anticipate
d
completio
n date

CETP Inhibitors
Dalcetrapib

DAL-Outcomes

Acute coronary syndromes (15,600)

2013

Anacetrapib

REVEAL

Stable coronary heart disease or risk

2017

equivalent (30,000)
Niacin
Niacin-laropipr
ant

HPS2-THRIVE

Stable vascular disease (25,000)

2013

Figure 2. Algorithm for the management of low serum high-density lipoprotein
(HDL) cholesterol. CAD - coronary artery disease; LDL - low-density

lipoprotein; NCEP - National Cholesterol Education Program; TZD
-thiazolidinedione. (Adapted from Circulation.22)

